Dissecting The Pseudoexfoliation Syndrome With Complementary Genetic, Proteomic And Biophysical Strategies
Funder
National Health and Medical Research Council
Funding Amount
$490,352.00
Summary
Pseudoexfoliation syndrome (PEX) is an eye condition in which flaky material deposits in the eye, greatly increasing the risk of cataract and glaucoma which can lead to blindness. PEX is also associated with heart disease, strokes and aneurysms. Cataract surgery in PEX patients has a higher rate of complications. In this project we will determine the nature of PEX material and why it forms. This knowlege will facilitate better diagnosis and treatment of PEX preventing associated blindness.
A Genome-wide Association Study In 2000 Glaucoma Cases With Matched Controls Using Equimoloar DNA Pools
Funder
National Health and Medical Research Council
Funding Amount
$610,267.00
Summary
Glaucoma is a common cause of loss of vision worldwide but we are unable to predict which people are at high risk of blindness. We aim to discover the genetic risk factors for glaucoma. We will use cutting edge genetic technology to assess the whole genome in thousands of patients with glaucoma. We hope to identify important new glaucoma genes, which could lead to the development of diagnostic tests and treatments which will provide the most cost-efficient ways to prevent glaucoma blindness.
A Genome-wide Association Scan To Identify Genetic Risk Factors For Sight Threatening Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$982,203.00
Summary
Diabetic eye disease is an important complication of diabetes that can lead to blindness. Very little is known about how diabetes causes eye disease, but genetics is known to play a role. We aim to identify genes that contribute to eye disease in diabetes patients. We will compare genes between patients with diabetes with and without severe diabetic eye disease using cutting edge genomic technology. We hope to be able to better predict risk of blindness and to move towards novel treatments.